Tests:Estradiol, Serum: Difference between revisions

Tests:Estradiol, Serum
No edit summary
No edit summary
 
(4 intermediate revisions by 4 users not shown)
Line 22: Line 22:
17 beta estradiol   
17 beta estradiol   
|-
|-
|Test Availability
|Availability
|Monday to Friday
|Monday to Friday
Weekend testing to be arranged
Weekend and public holiday testing by arrangment
|-
|-
|Turnaround Time
|Turnaround Time
Line 30: Line 30:
|-
|-
|Stability – Add test
|Stability – Add test
|
|24 hours unseperated
|-
|-
! colspan="2" |
! colspan="2" |
== Specimen Requirements ==
== Specimen Requirements ==
|-
|-
|Specimen Type
|Specimen  
|Serum
|Serum
Plasma
|-
|Specimen Transportation
|
|-
|-
|Preferred
|Preferred
|6 mL Plain <span style="background:#e30022"> Red-Top</span>
|<span style="background: #fbec5d">Yellow-Top</span> or <span style="background:#e30022"> Red-Top</span> tube
|-
|-
|Acceptable
|Acceptable
|5mL <span style="background: #fbec5d"> Yellow-Top</span>
|
|-
|-
|Unacceptable
|Unacceptable
|
|-
|Specimen Transportation
|
|
|-
|-
|Paediatric Requirements
|Paediatric Requirements
|0.5 mL in a <span style="background:#e30022"> Red-Top</span> or <span style="background: #fbec5d"> Yellow-Top</span> tube 
|0.5 mL in a <span style="background:#e30022"> Red-Top</span> microtainer
|-
|-
! colspan="2" |
! colspan="2" |
== Aliquot Requirements ==
== Aliquot Requirements ==
|-
|-
|Sample Type
|Sample  
|Serum 
|Serum 
|-
|Preferred Volume
|
|-
|-
|Minimum Volume
|Minimum Volume
Line 73: Line 74:
|
|
{| class="wikitable"
{| class="wikitable"
|Female
|Units
|pmol/L
|pmol/L
|-
| colspan="2" |Female :
|-
|-
|Follicular  phase
|Follicular  phase
Line 88: Line 91:
|<103          
|<103          
|-
|-
|Male           
| colspan="2" |
|-
|Male :          
|<160            
|<160            
|}
|}
Line 94: Line 99:
|-
|-
|Test Method
|Test Method
|Abbott Alinity Ci analyser using Abbott immunoassay reagent. 
|Abbott Alinity i series analyser using Abbott reagents.  Chemiluminescent microparticle immunoassay.
|-
|-
|Advanced Notice
|Advanced Notice
Line 105: Line 110:
== Comments ==
== Comments ==
|-
|-
| colspan="2" |Samples from patients receiving oestrogen replacement therapy including Premarin may yield spurious oestradiol results.  
| colspan="2" |Samples from patients receiving oestrogen replacement therapy including Premarin may yield spurious oestradiol results.  


   
   
|}
|}
{{DocMeta
| owner = Crossley1
| review_ping =
}}